Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28;62(2):99-105.
doi: 10.3960/jslrt.21038. Epub 2022 Mar 5.

Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?

Affiliations

Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?

Yoshito Nishimura et al. J Clin Exp Hematop. .

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a systemic disorder characterized by systemic inflammation and organ dysfunction associated with an increase in pro-inflammatory cytokines. Some patients with iMCD are positive for autoantibodies, although their significance and relationship with specific associated autoimmune diseases are unclear. This study retrospectively analyzed the clinicopathological features of iMCD patients focusing on autoantibodies. Among 63 iMCD patients in our database, 19 were positive for at least one autoantibody. Among the 19, we identified five with plasma cell type (PC)-iMCD lymph node histopathology and positive anti-phospholipid antibodies. These patients were likely to have thrombocytopenia, anasarca, fever, reticulin fibrosis or renal insufficiency, organomegaly (TAFRO) symptoms, and thrombotic events. The present study suggests that patients with undiagnosed or atypical autoimmune diseases, including anti-phospholipid syndrome (APS), were treated for iMCD. APS may present with thrombocytopenia or even multi-organ failure, which overlap with clinical presentations of iMCD. Due to differences in the treatment regimen and follow-up, recognition of the undiagnosed autoimmune disease process in those suspected of iMCD is essential. Our study highlights the importance of complete exclusion of differential diagnoses in patients with iMCD in their diagnostic workup.

Keywords: autoimmune, anti-phospholipid syndrome; idiopathic plasmacytic lymphadenopathy; multicentric Castleman disease.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Pathological findings of the included patients Case 1: Atrophic germinal center and expanded interfollicular area with mildly vascular proliferation (a, HE, ×100). The sheet-like proliferation of mature plasma cells with marked hemosiderin deposition. (b, HE, ×400) Case 5: Atrophic germinal centers and expansion of interfollicular area are observed (c, HE, ×100). The interfollicular area exhibits moderate to severely vascular proliferation and sheet-like infiltration of mature plasma cells (d, HE, ×200). Abbreviations: HE, hematoxylin and eosin.

Similar articles

Cited by

References

    1. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020; 135: 1353-1364. - PubMed
    1. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017; 129: 1646-1657. - PMC - PubMed
    1. Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: where are we now? Semin Diagn Pathol. 2016; 33: 294-306. - PMC - PubMed
    1. Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki. 2010; 51: 320-325. - PubMed
    1. Kojima M, Nakamura S, Shimizu K, et al. Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases. Int J Surg Pathol. 2004; 12: 25-30. - PubMed

MeSH terms

Substances

Supplementary concepts